uniQure (QURE) Insider Jack Kaye Buys $168K of Stock

Jack Kaye Expands Stake in uniQure N.V.

Jack Kaye recently acquired 5,295 shares of uniQure N.V. (NasdaqGS: QURE) on June 17, 2026. The purchase was executed at a price of $31.71 per share, totaling roughly $167,904.45. This trade comes as part of a wider wave of executive transactions within the biotechnology firm over the summer months.

Recent uniQure Insider Activity and Leadership Trades

Executive trading at the Amsterdam-headquartered biotech has been busy lately. Back on June 17, 2026, CEO Matthew Kapusta purchased 62,581 shares for $1,213,445.59, alongside another purchase of 4,128 shares on June 24, 2026. Other leaders have also adjusted their personal portfolios, including Chief Medical Officer Walid Abi-Saab, who sold 1,434 shares on June 26, 2026, for $67,197.24. These disclosures give a look into how key team members manage their holdings without signaling any broader market shift.

Stock Performance and Market Position

Shares of uniQure trade near $45.77, reflecting notable movement relative to its 52-week low of $8.73 and high of $71.50. The company carries a market capitalization of roughly $1.56 billion and an active clinical pipeline centered on rare disease treatments. Investors continue to monitor price action as the equity moves between its shorter-term moving averages and longer-term technical markers.

Wall Street Ratings and Price Targets

Analyst coverage includes multiple updates from major financial institutions over recent months. On October 5, 2026, Barclays shifted its stance by downgrading the stock to an Equal-Weight rating with a $28.00 price target. Earlier in the autumn, RBC Capital maintained an Outperform rating with a $48.00 target on October 2, 2026, while Goldman Sachs kept a Neutral rating and a $31.00 target on September 30, 2026. Across the broader analyst community, the stock holds a consensus strong buy recommendation with a mean price target of $61.46.

Understanding the Business Behind the Ticker

uniQure N.V. is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating conditions. Its portfolio features treatments such as HEMGENIX for hemophilia B alongside various pipeline candidates targeting Huntington's disease, epilepsy, and other rare disorders. The firm works to advance novel genetic medicines from its base in the Netherlands.

What to Watch Next for QURE

Market participants are looking toward the company's next scheduled earnings report on November 9, 2026, for further operational updates and pipeline progress. As always, insider transactions reported via SEC filings are backward-looking and reflect individual personal portfolio choices rather than corporate guidance.